PtdCho-PLC inhibition with D609 also resulted in enhanced HER2 internalization and lysosomal degradation, strong retardation of HER2 re-expression on the membrane, and reduced HER2 content in HER2-overexpressing breast cancer cells, suggesting that PtdCho-PLC inhibitors may be potential candidates for the treatment of HER2-amplified or trastuzumab-resistant breast cancers (105). Here, HSPG2 is linked to breast carcinoma.